News Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Market Closed - Nasdaq Other stock markets 03:59:38 2024-06-04 pm EDT			5-day change	1st Jan Change
35.82 ^USD	-0.49%		+26.77%	+73.22%

Jun. 04	Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target	MT
May. 24	Mizuho Securities Starts Cartesian Therapeutics With Buy Rating	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target	Jun. 04	MT
Mizuho Securities Starts Cartesian Therapeutics With Buy Rating	May. 24	MT
Cartesian Gets Regenerative Medicine Advanced Therapy Label for Myasthenia Gravis Drug Candidate	May. 22	MT
Cartesian Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy Designation for Descartes-08 for the Treatment of Myasthenia Gravis	May. 22	CI
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis	May. 22	AQ
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	May. 13	AQ
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	May. 08	AQ
Cartesian Therapeutics Announces New Employment Inducement Grants	May. 06	BU
Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target	Apr. 23	MT
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting	Apr. 22	BU
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference	Apr. 04	BU
Cartesian Therapeutics Announces New Employment Inducement Grants	Apr. 04	BU
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split	Mar. 28	AQ
Cartesian Therapeutics : Termination of Material Agreement - Form 8-K	Mar. 14	PU
Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	Mar. 14	CI
Cartesian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	Mar. 07	AQ
Cartesian Therapeutics to Participate in Upcoming Investor Conferences	Mar. 06	AQ
Cartesian Therapeutics Announces New Employment Inducement Grant	Mar. 05	AQ
Cartesian Therapeutics, Inc. Announces Resignation of Aymeric Sallin as Member of the Board of Director and Member of Compensation Committee	Mar. 05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Summary

Filters